Posted by Michael Wonder on 25 Mar 2024
Ultomiris approved in the US for the treatment of adults with neuromyelitis optica spectrum disorder
25 March 2024 - Unprecedented relapse risk reduction observed in CHAMPION-NMOSD trial underscores how Ultomiris may redefine patient journey for rare neurological disease.
Ultomiris (ravulizumab-cwvz) has been approved in the US as the first and only long-acting C5 complement inhibitor for the treatment of adult patients with anti-aquaporin-4 antibody positive neuromyelitis optica spectrum disorder.
